Clinical Trials: Anemia

Alabama

Birmingham; Research Site:
A Study of Intravenous (iv) Mircera in Hemodialysis Patients With Chronic Renal Anemia

Birmingham; Research Site:
A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.

Birmingham; Research Site:
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients

Birmingham; Research Site:
A Study of Mircera in Anemic Patients With Chronic Kidney Disease Not Yet on Dialysis.

Mobile; Research Site:
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients

Montgomery; Research Site:
A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.

Montgomery; Research Site:
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients

Arizona

Hot Springs; Research Site:[*]
A Study Comparing Mircera and Epoetin Alfa for the Treatment of Anemia in Dialysis Patients With Chronic Kidney Disease.

Pheonix; Research Site:[*]
A Study of Mircera in Hemoglobin Control of Patients Transitioning to Dialysis.

Pheonix; Research Site:[*]
A Study of Subcutaneous Mircera for the Treatment of Anemia in Peritoneal Dialysis Patients.

Phoenix; Hope Research Institute, LLC
Are you a new mother, struggling with Iron Deficiency Anemia?

Phoenix; Precision Trials, LLC[*]
Iron Deficiency anemia due to Post Partum or Heavy menstrual Bleeding

Arkansas

Hot Springs; Research Site:
A Study of Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients.

Hot Springs; Research Site:
A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.

California

Bakersfield; Research Site:
A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving Chemotherapy.

Concord; Research Site:
A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving Chemotherapy.

Covina; Research Site:
A Study of Intravenous or Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients

Covina; Research Site:
A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.

Encino; Research Site:
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients

Encino; Research Site:
A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.

Fullerton; Research Site:
A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving Chemotherapy.

Granada Hills; Research Site:
A Study of Subcutaneous Mircera in Patients With Chronic Kidney Disease, Not on Dialysis.

Greenbrae; Research Site:
A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving Chemotherapy.

Huntington Beach; Research Site:
A Study of Subcutaneous Mircera Once Monthly in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis.

Irvine; Research Site:
A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.

Irvine; Research Site:
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients

La Jolla; Research Site:
A Study of Subcutaneous Mircera in Patients With Chronic Kidney Disease, Not on Dialysis.

Long Beach; Research Site:
A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving Chemotherapy.

Los Alamitos; Research Site:
A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.

Los Alamitos; Research Site:
A Study of Intravenous or Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients

Los Angeles; Research Site:
A Study of Subcutaneous Mircera Once Monthly in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis.

Los Angeles; Research Site:
A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.

Los Angeles; Research Site:
A Study of Mircera in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis

Los Angeles; Research Site:
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients

Los Angeles; Research Site:
A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving Chemotherapy.

Los Angeles; Research Site:
A Study of Subcutaneous (sc) Mircera in Dialysis Patients With Chronic Renal Anemia.

Los Angeles; Research Site:
A Study of Intravenous (iv) Mircera in Hemodialysis Patients With Chronic Renal Anemia

Los Angeles; Research Site:
A Study of Intravenous or Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients

Mather; Research Site:
A Study of Mircera in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis

Monterey Park; Research Site:
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients

Monterey Park; Research Site:
A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.

Mountain View; Research Site:
A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.

Northridge; Research Site:
A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving Chemotherapy.

Oceanside; Research Site:
A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving Chemotherapy.

Pomona; Research Site:
A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving Chemotherapy.

Porterville; Research Site:
A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving Chemotherapy.

Riverside; Research Site:
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients

Riverside; Research Site:
A Study of Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients.

Sacramento; Research Site:
A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.

Sacramento; Research Site:
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients

San Diego ; Research Site:
A Study of Subcutaneous Mircera Once Monthly in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis.

San Diego ; Research Site:
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients

San Diego ; Research Site:
A Study of Intravenous or Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients

San Diego ; Research Site:
A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.

San Diego ; Research Site:
A Study of Mircera in Anemic Patients With Chronic Kidney Disease Not Yet on Dialysis.

San Francisco; Research Site:
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients

San Francisco; Research Site:
A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.

San Jose; Research Site:
A Study of Subcutaneous (sc) Mircera in Dialysis Patients With Chronic Renal Anemia.

San Jose; Research Site:
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients

San Jose; Research Site:
A Study of Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients.

Santa Barbara; Research Site:
A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving Chemotherapy.

Stanford; Research Site:
A Study of Subcutaneous Mircera Once Monthly in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis.

Stanford; Research Site:
A Study of Mircera in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis

Stanford; Research Site:
A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.

Vista; Research Site:
A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving Chemotherapy.

Whittier; Research Site:
A Study of Subcutaneous Mircera Once Monthly in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis.

Colorado

Colorado Springs; Research Site:
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients

Colorado Springs; Research Site:
A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.

Colorado Springs; Research Site:
A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving Chemotherapy.

Denver; Research Site:
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients

Denver; Research Site:
A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.

Lakewood; Research Site:
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients

Lakewood; Research Site:
A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.

Connecticut

Stamford; Research Site:
A Study of Mircera in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis

Stamford; Research Site:
A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.

Florida

Gainesville; Gainesville Hematology/ Oncology Associates
Once per Cycle Treatment of Anemia With Darbepoetin alfa with Iron in Subjects with Non-myeloid Malignancies ( malignancies not involving bone marrow)

Gainesville; Gainesville Hematology/Oncology Associates
A Phase II, Randomized, Open-Label, Comparative Study of Epoetin Alfa (Procrit) 80,000 Units or 120,000 Units Every Three Weeks Versus Darbepoetin (Aranesp) 500 mcg Every Three Weeks in Anemic Cancer Subjects Receiving Chemotherapy

Lauderdale Lakes; Research Site:
A Study of Subcutaneous Mircera in Patients With Chronic Kidney Disease, Not on Dialysis.

Ocala; Research Site:
A Study of Subcutaneous Mircera Once Monthly in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis.

Ocala; Renstar Medical Research
Anemia

Ocala; Research Site:
A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.

Ocala; Research Site:
A Study of Mircera in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis

Ocala; Research Site:
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients

Pembroke Pines; Research Site:
A Study of Subcutaneous Mircera Once Monthly in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis.

Pembroke Pines; Research Site:
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients

Pembroke Pines; Research Site:
A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.

Spring Hill; Research Site:
A Study of Subcutaneous Mircera Once Monthly in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis.

Tampa; Research Site:
A Study of Subcutaneous Mircera Once Monthly in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis.

Tampa; Research Site:
A Study of Intravenous or Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients

Georgia

Atlanta; Research Site:
A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.

Atlanta; Research Site:
A Study of Mircera for the Treatment of Anemia in Dialysis Patients

Atlanta; Research Site:
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients

Augusta; Research Site:
A Study of Subcutaneous Mircera Once Monthly in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis.

Augusta; Research Site:
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients

Augusta; Research Site:
A Study of Mircera for the Treatment of Anemia in Dialysis Patients

Augusta; Research Site:
A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.

Augusta; Research Site:
A Study of Subcutaneous Mircera in Patients With Chronic Kidney Disease, Not on Dialysis.

Blue Ridge; River Birch Research Alliance, LLC
A Multi-Center, Double-blind, Placebo-controlled, Safety and Preliminary Efficacy Study of IL-1 Trap (rilonacept) Administered Subcutaneously in Subjects with Non Dialysis-Dependent Chronic Kidney Disease (NDD-CKD) and Anemia

Macon ; Research Site:[*]
A Study of Mircera in Hemoglobin Control of Patients Transitioning to Dialysis.

Macon ; Research Site:[*]
A Study of Subcutaneous Mircera for the Treatment of Anemia in Peritoneal Dialysis Patients.

Hawaii

Honolulu; Research Site:
A Study of Intravenous or Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients

Honolulu; Research Site:
A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.

Idaho

Meridan; Research Site:
A Study of Subcutaneous Mircera Once Monthly in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis.

Illinois

Chicago; Research Site:
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients

Maywood; Research Site:
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients

Maywood; Research Site:
A Study of Intravenous (iv) Mircera in Hemodialysis Patients With Chronic Renal Anemia

Maywood; Research Site:
A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.

South Holland; Research Site:
A Study of Intravenous or Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients

South Holland; Research Site:
A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.

Iowa

Des Moines; Research Site:
A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving Chemotherapy.

Kentucky

Louisville; Research Site:
A Study of Subcutaneous Mircera Once Monthly in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis.

Louisville; Research Site:
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients

Louisville; Research Site:
A Study of Intravenous (iv) Mircera in Hemodialysis Patients With Chronic Renal Anemia

Louisville; Research Site:
A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.

Louisiana

Baton Rouge; Research Site:
A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.

Baton Rouge; Research Site:
A Study of Intravenous or Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients

New Orleans; Research Site:
A Study of Mircera for the Treatment of Anemia in Dialysis Patients

Ruston; Research Site:
A Study of Subcutaneous Mircera Once Monthly in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis.

Shreveport; Research Site:
A Study of Mircera in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis

Shreveport; Research Site:
A Study of Intravenous or Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients

Shreveport; Research Site:
A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.

Maryland

Baltimore; National Institute on Aging
Pilot Study of Epoetin Alfa in Idiopathic Anemia of Aging (IAA). This is a study that is evaluating a drug referred to as Epoetin Alfa (erythropoietin) for treatment in people with anemia of unknown cause associated with advancing age.

Baltimore; National Institute on Aging
An Anemia Clinic designed to evaluate a sequential referral population for the etiology of anemia across the adult age spectrum.

Rockville; Research Site:
A Study of Subcutaneous Mircera Once Monthly in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis.

Massachusetts

Boston; Research Site:
A Study of Subcutaneous Mircera in Patients With Chronic Kidney Disease, Not on Dialysis.

Boston; Research Site:
A Study of Subcutaneous Mircera Once Monthly in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis.

Boston; Research Site:[*]
A Study of Subcutaneous Mircera for the Treatment of Anemia in Peritoneal Dialysis Patients.

Boston; Research Site:[*]
A Study of Mircera in Hemoglobin Control of Patients Transitioning to Dialysis.

Boston; Research Site:
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients

Boston; Research Site:
A Study of Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients.

Boston; Research Site:
A Study of Intravenous or Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients

Boston; Research Site:
A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.

Boston; Research Site:
A Study of Subcutaneous (sc) Mircera in Dialysis Patients With Chronic Renal Anemia.

Springfield; Research Site:
A Study of Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients.

Springfield; Research Site:
A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.

Springfield; Research Site:
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients

Springfield; Research Site:
A Study of Mircera for the Treatment of Anemia in Dialysis Patients

Michigan

Detroit; Research Site:
A Study of Subcutaneous Mircera Once Monthly in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis.

Detroit; Research Site:
A Study of Mircera for the Treatment of Anemia in Dialysis Patients

Detroit; Research Site:
A Study of Intravenous (iv) Mircera in Hemodialysis Patients With Chronic Renal Anemia

Detroit; Research Site:
A Study of Mircera in Anemic Patients With Chronic Kidney Disease Not Yet on Dialysis.

Detroit; Research Site:
A Study of Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients.

Detroit; Research Site:
A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.

Detroit; Research Site:
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients

Detroit; Research Site:
A Study of Mircera in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis

Kalamazoo; Research Site:
A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.

Kalamazoo; Research Site:
A Study of Intravenous or Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients

Kalamazoo; Research Site:
A Study of Subcutaneous Mircera in Patients With Chronic Kidney Disease, Not on Dialysis.

Minnesota

Brooklyn Center; Research Site:
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients

Brooklyn Center; Research Site:
A Study of Intravenous (iv) Mircera in Hemodialysis Patients With Chronic Renal Anemia

Brooklyn Center; Research Site:
A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.

Mississippi

Columbus; Research Site:
A Study of Intravenous or Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients

Columbus; Research Site:
A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.

Tupelo; Research Site:
A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving Chemotherapy.

Tupelo; Research Site:
A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.

Tupelo; Research Site:
A Study of Intravenous or Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients

Missouri

St Louis; Research Site:
A Study of Subcutaneous Mircera Once Monthly in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis.

St Louis; Research Site:
A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.

St Louis; Research Site:
A Study of Intravenous or Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients

St. Louis; Saint Louis University
Diabetes Mellitus Type II with Chronic Kidney Disease and Anemia - Investigational study to evaluate an FDA approved injectable medication for patients with Anemia.

Montana

Great Falls; Research Site:
A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving Chemotherapy.

Kalispell; Research Site:
A Study of Subcutaneous Mircera in Patients With Chronic Kidney Disease, Not on Dialysis.

Nevada

Las Vegas; Research Site:
A Study of Intravenous (iv) Mircera in Hemodialysis Patients With Chronic Renal Anemia

Las Vegas; Research Site:
A Study of Mircera in Anemic Patients With Chronic Kidney Disease Not Yet on Dialysis.

Reno ; Research Site:
A Study of Mircera in Anemic Patients With Chronic Kidney Disease Not Yet on Dialysis.

New Jersey

Hackensack; Research Site:
A Study of Intravenous or Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients

Hackensack; Research Site:
A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.

Mount Laurel; Research Site:
A Study of Subcutaneous Mircera Once Monthly in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis.

Paterson; Research Site:
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients

Paterson; Research Site:
A Study of Intravenous (iv) Mircera in Hemodialysis Patients With Chronic Renal Anemia

Paterson; Research Site:
A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.

New Mexico

Albuquerque; Research Site:
A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.

Albuquerque; Research Site:
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients

New York

Bronx; Biomedical Research Alliance of New York
Iron Deficiency Anemia in Heavy Uterine Bleeding and Postpartum Patients - Adults and minors

Bronx; Research Site:
A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.

Bronx; Research Site:
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients

Bronx; Biomedical Research Alliance of New York
Anemia - Chronic kidney disease

Brooklyn; Research Site:
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients

Brooklyn; Research Site:
A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.

Brooklyn; Research Site:
A Study of Intravenous (iv) Mircera in Hemodialysis Patients With Chronic Renal Anemia

Brooklyn Center; Research Site:[*]
A Study Comparing Mircera and Epoetin Alfa for the Treatment of Anemia in Dialysis Patients With Chronic Kidney Disease.

Flushing; Research Site:
A Study of Subcutaneous Mircera Once Monthly in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis.

Flushing; Research Site:
A Study of Mircera in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis

Flushing; Research Site:
A Study of Intravenous or Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients

Flushing; Research Site:
A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.

Great Neck; Research Site:
A Study of Subcutaneous Mircera Once Monthly in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis.

Great Neck; Research Site:
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients

Great Neck; Research Site:
A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.

Jamaica; Biomedical Research Alliance of New York
Anemia - cancer

Jamaica; Biomedical Research Alliance of New York
Anemia- cancer

Lake Success; Biomedical Research Alliance of New York
Blood sample

Mineola; Research Site:
A Study of Mircera for the Treatment of Anemia in Dialysis Patients

Mineola; Research Site:
A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.

Mineola; Research Site:
A Study of Mircera in Anemic Patients With Chronic Kidney Disease Not Yet on Dialysis.

Mineola; Research Site:
A Study of Intravenous (iv) Mircera in Hemodialysis Patients With Chronic Renal Anemia

Mineola; Research Site:
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients

Mineola; Research Site:
A Study of Subcutaneous Mircera in Patients With Chronic Kidney Disease, Not on Dialysis.

New Hyde Park; Biomedical Research Alliance of New York
Blood sample

New Hyde Park; Biomedical Research Alliance of New York
Sickle Cell Anemia - Adults and minors

New Hyde Park; Biomedical Research Alliance of New York
Blood sample

New York; The Rockefeller University Hospital
Entrance into the International Fanconi Anemia Registry (IFAR)

New York; Research Site:
A Study of Mircera for the Treatment of Anemia in Dialysis Patients

New York; Research Site:
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients

New York; Research Site:
A Study of Intravenous or Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients

New York; Research Site:
A Study of Intravenous (iv) Mircera in Hemodialysis Patients With Chronic Renal Anemia

New York; Research Site:
A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.

Orchard Park; Research Site:
A Study of Subcutaneous Mircera Once Monthly in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis.

Orchard Park; Research Site:
A Study of Intravenous or Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients

Orchard Park; Research Site:
A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.

Orchard Park; Research Site:
A Study of Subcutaneous Mircera in Patients With Chronic Kidney Disease, Not on Dialysis.

Rochester; Research Site:
A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving Chemotherapy.

Rockville Centre; Research Site:
A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving Chemotherapy.

Springfield Gardens; Research Site:
A Study of Subcutaneous Mircera Once Monthly in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis.

Staten Island; Biomedical Research Alliance of New York
Blood Sample

Staten Island; Staten Island Urological Research, P.C.
Clinical Research Study for People with Cancer-related Anemia.

Stony Brook; Research Site:
A Study of Subcutaneous Mircera Once Monthly in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis.

Stony Brook; Research Site:
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients

North Carolina

Chapel Hill; Research Site:
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients

Chapel Hill; Research Site:
A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.

Charlotte; Research Site:
A Study of Subcutaneous Mircera Once Monthly in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis.

Hickory ; Research Site:
A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving Chemotherapy.

Mount Airy; Research Site:
A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.

Raleigh; Wake Research Associates
Do you have Low Iron?

Raleigh; Research Site:
A Study of Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients.

Raleigh; Research Site:
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients

Raleigh; Research Site:
A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.

Raleigh; Research Site:
A Study of Subcutaneous Mircera in Patients With Chronic Kidney Disease, Not on Dialysis.

Winston-Salem; Research Site:
A Study of Subcutaneous Mircera Once Monthly in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis.

Winston-Salem; Research Site:[*]
A Study of Subcutaneous Mircera for the Treatment of Anemia in Peritoneal Dialysis Patients.

Winston-Salem; Research Site:[*]
A Study of Mircera in Hemoglobin Control of Patients Transitioning to Dialysis.

Winston-Salem; Research Site:
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients

Winston-Salem; Research Site:
A Study of Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients.

North Dakota

Bismarck; Research Site:
A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving Chemotherapy.

Fargo; Research Site:
A Study of Subcutaneous Mircera Once Monthly in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis.

Ohio

Canton; Research Site:
A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving Chemotherapy.

Cincinnati; Research Site:
A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.

Cincinnati; Research Site:
A Study of Mircera in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis

Cincinnati; Research Site:
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients

Cincinnati; Cincinnati Children's Hospital Medical Center/Cincinnati Children's Research Foundation
A Research Study to Test the Safety of Reinfusing Autologous Bone Marrow, Cord Blood or Peripheral Blood Cells in Patients With Fanconi Anemia

Cincinnati; Cincinnati Children's Hospital Medical Center/Cincinnati Children's Research Foundation
Gene Transfer for Patients with Fanconi Anemia, Genotype A: A Pilot Study

Cincinnati; Cincinnati Children's Hospital Medical Center/Cincinnati Children's Research Foundation
A Pilot Trial of Oxandrolone for the Treatment of Bone Marrow Aplasia in Fanconi Anemia

Cincinnati; Cincinnati Children's Hospital Medical Center/Cincinnati Children's Research Foundation
Collection of Hematopoietic Cells from Patients with Fanconi Anemia (FA) for Future Autologous Reinfusion and Research

Cleveland; Research Site:
A Study of Intravenous or Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients

Cleveland; Research Site:
A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.

Cleveland; Research Site:
A Study of Subcutaneous (sc) Mircera in Dialysis Patients With Chronic Renal Anemia.

Columbus; Research Site:
A Study of Subcutaneous Mircera in Patients With Chronic Kidney Disease, Not on Dialysis.

Toledo; Research Site:
A Study of Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients.

Toledo; Research Site:
A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.

Toledo; Research Site:
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients

Oregon

Medford; Medford Women's Clinic
Anemia due to Heavy Uterine Bleeding

Medford; Medford Women's Clinic
Anemia-Chronic Kidney Disease

Oregon City; Research Site:
A Study of Intravenous or Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients

Oregon City; Research Site:
A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.

Portland; Research Site:
A Study of Subcutaneous Mircera in Patients With Chronic Kidney Disease, Not on Dialysis.

Portland; Research Site:
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients

Portland; Research Site:
A Study of Mircera in Anemic Patients With Chronic Kidney Disease Not Yet on Dialysis.

Portland; Research Site:
A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.

Portland; Research Site:
A Study of Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients.

Pennsylvania

Allentown; Research Site:
A Study of Mircera in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis

Allentown; Research Site:
A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.

Allentown; Research Site:
A Study of Subcutaneous Mircera in Patients With Chronic Kidney Disease, Not on Dialysis.

Erie; Research Site:
A Study of Intravenous or Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients

Erie; Research Site:
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients

Erie; Research Site:
A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.

Hershey; Research Site:
A Study of Subcutaneous Mircera in Patients With Chronic Kidney Disease, Not on Dialysis.

Kingston ; Research Site:
A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving Chemotherapy.

Lewistown; Research Site:
A Study of Intravenous or Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients

Lewistown; Research Site:
A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.

Lewistown; Research Site:
A Study of Subcutaneous Mircera in Patients With Chronic Kidney Disease, Not on Dialysis.

Philadelphia; Research Site:
A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving Chemotherapy.

Philadelphia; Research Site:
A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.

Philadelphia; Research Site:
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients

Philadelphia; Research Site:
A Study of Intravenous or Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients

Pittsburgh; Research Site:
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients

Pittsburgh; Research Site:
A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.

Rhode Island

Providence; Research Site:
A Study of Subcutaneous Mircera Once Monthly in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis.

Providence; Research Site:
A Study of Subcutaneous Mircera in Patients With Chronic Kidney Disease, Not on Dialysis.

South Carolina

Aiken; Research Site:
A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving Chemotherapy.

Columbia; Research Site:
A Study of Intravenous or Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients

Columbia; Research Site:
A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.

Columbia; Research Site:
A Study of Mircera in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis

Orangeburg; Research Site:
A Study of Subcutaneous Mircera Once Monthly in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis.

Orangeburg; Research Site:
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients

Orangeburg; Research Site:
A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.

Tennessee

Chatanooga; Research Site:[*]
A Study of Mircera in Hemoglobin Control of Patients Transitioning to Dialysis.

Chattanooga; Research Site:
A Study of Subcutaneous Mircera Once Monthly in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis.

Chattanooga; Research Site:
A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.

Chattanooga; Research Site:
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients

Chattanooga; Research Site:
A Study of Subcutaneous Mircera in Patients With Chronic Kidney Disease, Not on Dialysis.

Knoxville; Research Site:
A Study of Subcutaneous Mircera Once Monthly in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis.

Memphis ; Research Site:
A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving Chemotherapy.

Nashville; Research Site:
A Study of Subcutaneous Mircera Once Monthly in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis.

Nashville; Research Site:
A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.

Nashville; Research Site:
A Study of Mircera in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis

Nashville; Research Site:
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients

Nashville; Research Site:
A Study of Intravenous (iv) Mircera in Hemodialysis Patients With Chronic Renal Anemia

Texas

Austin; Research Site:
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients

Austin; Research Site:
A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.

Austin; Research Site:
A Study of Mircera in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis

Dallas; Research Site:
A Study of Subcutaneous Mircera Once Monthly in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis.

Dallas; Research Site:
A Study of Mircera in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis

Dallas; Research Site:
A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.

Dallas; Research Site:
A Study of Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients.

Dallas; Research Site:
A Study of Subcutaneous Mircera in Patients With Chronic Kidney Disease, Not on Dialysis.

Houston; Research Site:
A Study of Subcutaneous Mircera Once Monthly in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis.

Houston; Research Site:
A Study of Mircera for the Treatment of Anemia in Dialysis Patients

Houston; Research Site:
A Study of Mircera in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis

Houston; Research Site:
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients

Houston; Research Site:
A Study of Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients.

Houston; Research Site:
A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving Chemotherapy.

Houston; Research Site:
A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.

Houston; Research Site:
A Study of Subcutaneous (sc) Mircera in Dialysis Patients With Chronic Renal Anemia.

Mcallen; Research Site:
A Study of Subcutaneous Mircera in Patients With Chronic Kidney Disease, Not on Dialysis.

San Antonio; Clinical Trials of Texas, Inc.
Anemia due to heavy uterine bleeding or post partum

San Antonio; Research Site:
A Study of Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients.

San Antonio; Research Site:
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients

Vermont

Bennington; Research Site:
A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving Chemotherapy.

Burlington; Research Site:
A Study of Subcutaneous Mircera Once Monthly in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis.

Burlington; Research Site:
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients

Burlington; Research Site:
A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.

Burlington; Research Site:
A Study of Mircera for the Treatment of Anemia in Dialysis Patients

Burlington; Research Site:
A Study of Mircera in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis

Virginia

Charlottesville; Research Site:
A Study of Intravenous or Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients

Chesapeake ; Research Site:[*]
A Study Comparing Mircera and Epoetin Alfa for the Treatment of Anemia in Dialysis Patients With Chronic Kidney Disease.

Fairfax ; Research Site:
A Study of Subcutaneous Mircera Once Monthly in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis.

Fairfax ; Research Site:
A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.

Fairfax ; Research Site:
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients

Norfolk ; Research Site:
A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.

Norfolk ; Research Site:
A Study of Intravenous or Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients

Norfolk ; Research Site:
A Study of Mircera for the Treatment of Anemia in Dialysis Patients

Richmond; Research Site:
A Study of Subcutaneous Mircera Once Monthly in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis.

Richmond; Research Site:
A Study of Subcutaneous Mircera in Patients With Chronic Kidney Disease, Not on Dialysis.

Richmond; Research Site:
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients

Salem; Research Site:
A Study of Mircera in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis

Salem; Research Site:
A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.

Salem; Research Site:
A Study of Subcutaneous Mircera in Patients With Chronic Kidney Disease, Not on Dialysis.

Washington

Tacoma; Tacoma Women's Specialists Clinical Research Center
1VITO7017: A Multi-Center, Randomized, Controlled Study to Investigate the Safety and Tolerability of Intravenous Ferric Carboxymaltose (FCM) vs. Standard Medical Care in Treating Iron Deficiency Anemia in Heavy Uterine Bleeding and Postpartum Patients.

Tacoma; Tacoma Women's Specialists Clinical Research Center
1VITO7017: A Multi-Center, Randomized, Controlled Study to Investigate the Safety and Tolerability of Intravenous Ferric Carboxymaltose (FCM) vs. Standard Medical Care in Treating Iron Deficiency Anemia in Heavy Uterine Bleeding and Postpartum Patients.

Tacoma; Research Site:
A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving Chemotherapy.

Washington, DC

Washington; Research Site:
A Study of Subcutaneous Mircera in Patients With Chronic Kidney Disease, Not on Dialysis.

West Virginia

Morgantown; Research Site:
A Study of Mircera in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis

Morgantown; Research Site:
A Study of Intravenous (iv) Mircera in Hemodialysis Patients With Chronic Renal Anemia

Morgantown; Research Site:
A Study of Subcutaneous (sc) Mircera in Dialysis Patients With Chronic Renal Anemia.

Morgantown; Research Site:
A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.

Morgantown; Research Site:
A Study of Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients.

Morgantown; Research Site:
A Study of Subcutaneous Mircera in Patients With Chronic Kidney Disease, Not on Dialysis.

Wisconsin

Marshfield; Research Site:
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients

International

Buenos Aires , Argentina; Research Site:
LATINO Study: A Study of Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.

Córdoba, Argentina; Research Site:
LATINO Study: A Study of Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.

Santa Fe, Argentina; Research Site:
LATINO Study: A Study of Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.

Adelaide, Australia; Research Site:
A Study of Subcutaneous Mircera Once Monthly in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis.

Adelaide, Australia; Research Site:
A Study of Subcutaneous Mircera, Versus no ESA Therapy, in the Treatment of Anemia in Patients With Chronic Kidney Disease After Kidney Transplant.

Adelaide, Australia; Research Site:
A Study of Mircera for the Maintenance Treatment of Anemia in Dialysis Patients.

Adelaide, Australia; Research Site:
A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving First Line Chemotherapy.

Adelaide, Australia; Research Site:
COMFORT Study: A Crossover Study of NeoRecormon (Epoetin Beta) and Darbepoetin Alfa in Patients With Renal Anemia.

Adelaide, Australia; Research Site:
A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving Chemotherapy.

Brisbane, Australia; Research Site:
A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving First Line Chemotherapy.

Brisbane, Australia; Research Site:
A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving Chemotherapy.

Gosford, Australia; Research Site:
A Study of Subcutaneous Mircera Once Monthly in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis.

Gosford, Australia; Research Site:
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients.

Gosford, Australia; Research Site:
COMFORT Study: A Crossover Study of NeoRecormon (Epoetin Beta) and Darbepoetin Alfa in Patients With Renal Anemia.

Gosford, Australia; Research Site:
A Study of Mircera for the Maintenance Treatment of Anemia in Dialysis Patients.

Gosford, Australia; Research Site:
A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.

Liverpool, Australia; Research Site:
COMFORT Study: A Crossover Study of NeoRecormon (Epoetin Beta) and Darbepoetin Alfa in Patients With Renal Anemia.

Liverpool, Australia; Research Site:
A Study of Mircera in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis

Liverpool, Australia; Research Site:
A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.

Liverpool, Australia; Research Site:
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients.

Melbourne, Australia; Research Site:
A Study of Subcutaneous Mircera Once Monthly in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis.

Melbourne, Australia; Research Site:
A Study of Subcutaneous Mircera, Versus no ESA Therapy, in the Treatment of Anemia in Patients With Chronic Kidney Disease After Kidney Transplant.

Melbourne, Australia; Research Site:
COMFORT Study: A Crossover Study of NeoRecormon (Epoetin Beta) and Darbepoetin Alfa in Patients With Renal Anemia.

Melbourne, Australia; Research Site:
A Study of Mircera for the Maintenance Treatment of Anemia in Dialysis Patients.

Melbourne, Australia; Research Site:
A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving First Line Chemotherapy.

Melbourne, Australia; Research Site:
A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.

Melbourne, Australia; Research Site:
A Study of Mircera in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis

Melbourne, Australia; Research Site:
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients.

Melbourne, Australia; Research Site:
A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving Chemotherapy.

Parkville, Australia; Research Site:
A Study of Subcutaneous Mircera Once Monthly in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis.

Parkville, Australia; Research Site:
A Study of Subcutaneous Mircera, Versus no ESA Therapy, in the Treatment of Anemia in Patients With Chronic Kidney Disease After Kidney Transplant.

Parkville, Australia; Research Site:
COMFORT Study: A Crossover Study of NeoRecormon (Epoetin Beta) and Darbepoetin Alfa in Patients With Renal Anemia.

Parkville, Australia; Research Site:
A Study of Mircera for the Maintenance Treatment of Anemia in Dialysis Patients.

Parkville, Australia; Research Site:
A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.

Parkville, Australia; Research Site:
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients.

Parkville, Australia; Research Site:
A Study of Mircera in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis

Perth, Australia; Research Site:
A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.

Perth, Australia; Research Site:
A Study of Mircera in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis

St. Leonards, Australia; Research Site:
COMFORT Study: A Crossover Study of NeoRecormon (Epoetin Beta) and Darbepoetin Alfa in Patients With Renal Anemia.

Sydney, Australia; Research Site:
A Study of Subcutaneous Mircera, Versus no ESA Therapy, in the Treatment of Anemia in Patients With Chronic Kidney Disease After Kidney Transplant.

Sydney, Australia; Research Site:
COMFORT Study: A Crossover Study of NeoRecormon (Epoetin Beta) and Darbepoetin Alfa in Patients With Renal Anemia.

Sydney, Australia; Research Site:
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients.

Sydney, Australia; Research Site:
A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.

Woolloongabba, Australia; Research Site:
COMFORT Study: A Crossover Study of NeoRecormon (Epoetin Beta) and Darbepoetin Alfa in Patients With Renal Anemia.

Woolloongabba, Australia; Research Site:
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients.

Woolloongabba, Australia; Research Site:
A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.

Woolloongabba, Australia; Research Site:
A Study of Mircera for the Maintenance Treatment of Anemia in Dialysis Patients.

Baden, Austria; Research Site:
MIRACLE Study: A Study Of Once-Monthly Intravenous Mircera in Hemodialysis Patients With Chronic Renal Anemia.

Bludesch, Austria; Research Site:
(BRAVE Study) - A Study of NeoRecormon (Epoetin Beta) in Patients With Metastatic Breast Cancer

Feldkirch, Austria; Research Site:
MIRACLE Study: A Study Of Once-Monthly Intravenous Mircera in Hemodialysis Patients With Chronic Renal Anemia.

Graz, Austria; Research Site:
MIRACLE Study: A Study Of Once-Monthly Intravenous Mircera in Hemodialysis Patients With Chronic Renal Anemia.

Graz, Austria; Research Site:
A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.

Graz, Austria; Research Site:
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients.

Graz, Austria; Research Site:
(BRAVE Study) - A Study of NeoRecormon (Epoetin Beta) in Patients With Metastatic Breast Cancer

Kufstein, Austria; Research Site:
MIRACLE Study: A Study Of Once-Monthly Intravenous Mircera in Hemodialysis Patients With Chronic Renal Anemia.

Linz, Austria; Research Site:
MIRACLE Study: A Study Of Once-Monthly Intravenous Mircera in Hemodialysis Patients With Chronic Renal Anemia.

Linz, Austria; Research Site:
A Study of Treatment With NeoRecormon (Epoetin Beta) in Patients With Chronic Renal Anemia

Linz, Austria; Research Site:
A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving First Line Chemotherapy.

Linz, Austria; Research Site:
(ACORD Study) - A Study of NeoRecormon (Epoetin Beta) in Patients With Early Diabetic Nephropathy

Linz, Austria; Research Site:
A Study of Mircera for the Maintenance Treatment of Anemia in Dialysis Patients.

Salzburg, Austria; Research Site:
MIRACLE Study: A Study Of Once-Monthly Intravenous Mircera in Hemodialysis Patients With Chronic Renal Anemia.

Salzburg, Austria; Research Site:
A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving First Line Chemotherapy.

St Pölten, Austria; Research Site:
MIRACLE Study: A Study Of Once-Monthly Intravenous Mircera in Hemodialysis Patients With Chronic Renal Anemia.

St Pölten, Austria; Research Site:
A Study of Treatment With NeoRecormon (Epoetin Beta) in Patients With Chronic Renal Anemia

Steyr, Austria; Research Site:
MIRACLE Study: A Study Of Once-Monthly Intravenous Mircera in Hemodialysis Patients With Chronic Renal Anemia.

Wien, Austria; Research Site:
MIRACLE Study: A Study Of Once-Monthly Intravenous Mircera in Hemodialysis Patients With Chronic Renal Anemia.

Wien, Austria; Research Site:
A Study of Mircera for the Maintenance Treatment of Anemia in Dialysis Patients.

Wien, Austria; Research Site:
A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving First Line Chemotherapy.

Wien, Austria; Research Site:
(BRAVE Study) - A Study of NeoRecormon (Epoetin Beta) in Patients With Metastatic Breast Cancer

Aalst, Belgium; Research Site:
A Study of Subcutaneous Mircera Once Monthly in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis.

Aalst, Belgium; Research Site:
A Study of Subcutaneous Mircera in Patients With Chronic Kidney Disease, Not on Dialysis.

Aalst, Belgium; Research Site:
A Study of Subcutaneous Mircera for the Maintenance Treatment of Patients With Chronic Renal Anemia Not Receiving ESA Treatment or Dialysis.

Aalst, Belgium; Research Site:
A Study of NeoRecormon(Epoetin Beta)in Anemic Patients With Solid Tumors

Aalst, Belgium; Research Site:
A Study of Mircera for the Maintenance Treatment of Anemia in Dialysis Patients.

Aalst, Belgium; Research Site:
A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving First Line Chemotherapy.

Aalst, Belgium; Research Site:
(BRAVE Study) - A Study of NeoRecormon (Epoetin Beta) in Patients With Metastatic Breast Cancer

Aalst, Belgium; Research Site:
A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.

Aalst, Belgium; Research Site:
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients.

Antwerpen, Belgium; Research Site:
A Study of Subcutaneous Mircera for the Maintenance Treatment of Patients With Chronic Renal Anemia Not Receiving ESA Treatment or Dialysis.

Antwerpen, Belgium; Research Site:
A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving Chemotherapy.

Assebroek, Belgium; Research Site:
A Study of Subcutaneous Mircera for the Maintenance Treatment of Patients With Chronic Renal Anemia Not Receiving ESA Treatment or Dialysis.

Ath, Belgium; Research Site:
A Study of Subcutaneous Mircera for the Maintenance Treatment of Patients With Chronic Renal Anemia Not Receiving ESA Treatment or Dialysis.

Baudour, Belgium; Research Site:
A Study of Subcutaneous Mircera for the Maintenance Treatment of Patients With Chronic Renal Anemia Not Receiving ESA Treatment or Dialysis.

Bonheiden, Belgium; Research Site:
A Study of Subcutaneous Mircera for the Maintenance Treatment of Patients With Chronic Renal Anemia Not Receiving ESA Treatment or Dialysis.

Bonheiden, Belgium; Research Site:
A Study of NeoRecormon(Epoetin Beta)in Anemic Patients With Solid Tumors

Brugge, Belgium; Research Site:
A Study of Treatment With NeoRecormon (Epoetin Beta) in Patients With Chronic Renal Anemia

Brugge, Belgium; Research Site:
A Study of NeoRecormon(Epoetin Beta)in Anemic Patients With Solid Tumors

Bruxelles, Belgium; Research Site:
A Study of Subcutaneous Mircera for the Maintenance Treatment of Patients With Chronic Renal Anemia Not Receiving ESA Treatment or Dialysis.

Bruxelles, Belgium; Research Site:
A Study of Treatment With NeoRecormon (Epoetin Beta) in Patients With Chronic Renal Anemia

Bruxelles, Belgium; Research Site:
A Study of Mircera in Patients With Non-Hodgkin's Lymphoma and Anemia.

Bruxelles, Belgium; Research Site:
A Study of Mircera for the Maintenance Treatment of Anemia in Dialysis Patients.

Bruxelles, Belgium; Research Site:
A Study of NeoRecormon(Epoetin Beta)in Anemic Patients With Solid Tumors

Bruxelles, Belgium; Research Site:
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients.

Bruxelles, Belgium; Research Site:
A Study of Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients.

Bruxelles, Belgium; Research Site:
A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.

Charleroi, Belgium; Research Site:
A Study of Subcutaneous Mircera for the Maintenance Treatment of Patients With Chronic Renal Anemia Not Receiving ESA Treatment or Dialysis.

Charleroi, Belgium; Research Site:
A Study of NeoRecormon(Epoetin Beta)in Anemic Patients With Solid Tumors

Dendermonde, Belgium; Research Site:
A Study of Subcutaneous Mircera for the Maintenance Treatment of Patients With Chronic Renal Anemia Not Receiving ESA Treatment or Dialysis.

Dendermonde, Belgium; Research Site:
A Study of NeoRecormon(Epoetin Beta)in Anemic Patients With Solid Tumors

Edegem, Belgium; Research Site:
A Study of Subcutaneous Mircera, Versus no ESA Therapy, in the Treatment of Anemia in Patients With Chronic Kidney Disease After Kidney Transplant.

Edegem, Belgium; Research Site:
A Study of Subcutaneous Mircera for the Maintenance Treatment of Patients With Chronic Renal Anemia Not Receiving ESA Treatment or Dialysis.

Edegem, Belgium; Research Site:
A Study of Treatment With NeoRecormon (Epoetin Beta) in Patients With Chronic Renal Anemia

Edegem, Belgium; Research Site:
A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving First Line Chemotherapy.

Edegem, Belgium; Research Site:
A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.

Edegem, Belgium; Research Site:
A Study of Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients.

Geel, Belgium; Research Site:
A Study of NeoRecormon(Epoetin Beta)in Anemic Patients With Solid Tumors

Genk, Belgium; Research Site:
A Study of Subcutaneous Mircera for the Maintenance Treatment of Patients With Chronic Renal Anemia Not Receiving ESA Treatment or Dialysis.

Gent, Belgium; Research Site:
A Study of Subcutaneous Mircera, Versus no ESA Therapy, in the Treatment of Anemia in Patients With Chronic Kidney Disease After Kidney Transplant.

Gent, Belgium; Research Site:
A Study of Subcutaneous Mircera for the Maintenance Treatment of Patients With Chronic Renal Anemia Not Receiving ESA Treatment or Dialysis.

Gent, Belgium; Research Site:
A Study of Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients.

Gent, Belgium; Research Site:
A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.

Gosselies, Belgium; Research Site:
A Study of NeoRecormon(Epoetin Beta)in Anemic Patients With Solid Tumors

Haine-Saint-Paul, Belgium; Research Site:
A Study of Subcutaneous Mircera for the Maintenance Treatment of Patients With Chronic Renal Anemia Not Receiving ESA Treatment or Dialysis.

Hasselt, Belgium; Research Site:
A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.

Hasselt, Belgium; Research Site:
A Study of Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients.

Hornu, Belgium; Research Site:
A Study of Subcutaneous Mircera for the Maintenance Treatment of Patients With Chronic Renal Anemia Not Receiving ESA Treatment or Dialysis.

Huy, Belgium; Research Site:
A Study of Subcutaneous Mircera for the Maintenance Treatment of Patients With Chronic Renal Anemia Not Receiving ESA Treatment or Dialysis.

Ieper, Belgium; Research Site:
A Study of Subcutaneous Mircera for the Maintenance Treatment of Patients With Chronic Renal Anemia Not Receiving ESA Treatment or Dialysis.

Kortrijk, Belgium; Research Site:
A Study of NeoRecormon(Epoetin Beta)in Anemic Patients With Solid Tumors

La Louvière, Belgium; Research Site:
A Study of Subcutaneous Mircera for the Maintenance Treatment of Patients With Chronic Renal Anemia Not Receiving ESA Treatment or Dialysis.

Leuven, Belgium; Research Site:
A Study of Subcutaneous Mircera, Versus no ESA Therapy, in the Treatment of Anemia in Patients With Chronic Kidney Disease After Kidney Transplant.

Leuven, Belgium; Research Site:
A Study of Subcutaneous Mircera for the Maintenance Treatment of Patients With Chronic Renal Anemia Not Receiving ESA Treatment or Dialysis.

Leuven, Belgium; Research Site:
A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.

Leuven, Belgium; Research Site:
A Study of Mircera in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis

Leuven, Belgium; Research Site:
(MARCH Study) - A Study of NeoRecormon (Epoetin Beta) in Patients With Advanced Cervical Cancer

Leuven, Belgium; Research Site:
A Study of Mircera in Patients With Non-Hodgkin's Lymphoma and Anemia.

Leuven, Belgium; Research Site:
(BRAVE Study) - A Study of NeoRecormon (Epoetin Beta) in Patients With Metastatic Breast Cancer

Liege, Belgium; Research Site:
A Study of Subcutaneous Mircera for the Maintenance Treatment of Patients With Chronic Renal Anemia Not Receiving ESA Treatment or Dialysis.

Liege, Belgium; Research Site:
A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving Chemotherapy.

Liege, Belgium; Research Site:
A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving First Line Chemotherapy.

Liege, Belgium; Research Site:
A Study of Intravenous or Subcutaneous Mircera in Chronic Kidney Disease Patients With Renal Anemia.

Liege, Belgium; Research Site:
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients.

Liege, Belgium; Research Site:
A Study of NeoRecormon(Epoetin Beta)in Anemic Patients With Solid Tumors

Liège, Belgium; Research Site:
A Study of Subcutaneous Mircera for the Maintenance Treatment of Patients With Chronic Renal Anemia Not Receiving ESA Treatment or Dialysis.

Merksem, Belgium; Research Site:
A Study of NeoRecormon(Epoetin Beta)in Anemic Patients With Solid Tumors

Mons, Belgium; Research Site:
A Study of NeoRecormon(Epoetin Beta)in Anemic Patients With Solid Tumors

Mons, Belgium; Research Site:
A Study of NeoRecormon (Epoetin Beta) in the Treatment of Patients on Hemodialysis

Mont-Godinne, Belgium; Research Site:
A Study of NeoRecormon(Epoetin Beta)in Anemic Patients With Solid Tumors

Mouscron, Belgium; Research Site:
A Study of Subcutaneous Mircera for the Maintenance Treatment of Patients With Chronic Renal Anemia Not Receiving ESA Treatment or Dialysis.

Namur, Belgium; Research Site:
A Study of NeoRecormon(Epoetin Beta)in Anemic Patients With Solid Tumors

Namur, Belgium; Research Site:
(BRAVE Study) - A Study of NeoRecormon (Epoetin Beta) in Patients With Metastatic Breast Cancer

Oostende, Belgium; Research Site:
A Study of NeoRecormon(Epoetin Beta)in Anemic Patients With Solid Tumors

Roeselare, Belgium; Research Site:
A Study of Subcutaneous Mircera Once Monthly in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis.

Roeselare, Belgium; Research Site:
A Study of Subcutaneous Mircera for the Maintenance Treatment of Patients With Chronic Renal Anemia Not Receiving ESA Treatment or Dialysis.

Roeselare, Belgium; Research Site:
A Study of Subcutaneous Mircera in Patients With Chronic Kidney Disease, Not on Dialysis.

Roeselare, Belgium; Research Site:
A Study of NeoRecormon (Epoetin Beta) in the Treatment of Patients on Hemodialysis

Roeselare, Belgium; Research Site:
A Study of Mircera for the Maintenance Treatment of Anemia in Dialysis Patients.

Roeselare, Belgium; Research Site:
A Study of NeoRecormon(Epoetin Beta)in Anemic Patients With Solid Tumors

Ronse, Belgium; Research Site:
A Study of NeoRecormon(Epoetin Beta)in Anemic Patients With Solid Tumors

Sint-Niklaas, Belgium; Research Site:
A Study of NeoRecormon(Epoetin Beta)in Anemic Patients With Solid Tumors

Tournai, Belgium; Research Site:
A Study of Subcutaneous Mircera for the Maintenance Treatment of Patients With Chronic Renal Anemia Not Receiving ESA Treatment or Dialysis.

Tournai, Belgium; Research Site:
A Study of NeoRecormon(Epoetin Beta)in Anemic Patients With Solid Tumors

Turnhout, Belgium; Research Site:
A Study of Subcutaneous Mircera for the Maintenance Treatment of Patients With Chronic Renal Anemia Not Receiving ESA Treatment or Dialysis.

Verviers, Belgium; Research Site:
A Study of Subcutaneous Mircera for the Maintenance Treatment of Patients With Chronic Renal Anemia Not Receiving ESA Treatment or Dialysis.

Verviers, Belgium; Research Site:
A Study of NeoRecormon(Epoetin Beta)in Anemic Patients With Solid Tumors

Verviers, Belgium; Research Site:
A Study of NeoRecormon (Epoetin Beta) in the Treatment of Patients on Hemodialysis

Vilvoorde, Belgium; Research Site:
A Study of NeoRecormon(Epoetin Beta)in Anemic Patients With Solid Tumors

Wilrijk, Belgium; Research Site:
(BRAVE Study) - A Study of NeoRecormon (Epoetin Beta) in Patients With Metastatic Breast Cancer

Wilrijk, Belgium; Research Site:
A Study of Mircera in Patients With Non-Hodgkin's Lymphoma and Anemia.

Wilrijk, Belgium; Research Site:
A Study of NeoRecormon(Epoetin Beta)in Anemic Patients With Solid Tumors

Zottegem, Belgium; Research Site:
A Study of NeoRecormon (Epoetin Beta) in the Treatment of Patients on Hemodialysis

Aracajú, Brazil; Research Site:
LATINO Study: A Study of Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.

Belo Horizonte, Brazil; Research Site:
A Study of Subcutaneous Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.

Belo Horizonte, Brazil; Research Site:
(BRAVE Study) - A Study of NeoRecormon (Epoetin Beta) in Patients With Metastatic Breast Cancer

Brasilia, Brazil; Research Site:
A Study of Subcutaneous Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.

Campinas, Brazil; Research Site:
A Study of Subcutaneous Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.

Campinas, Brazil; Research Site:
A Study of Subcutaneous Mircera, Versus no ESA Therapy, in the Treatment of Anemia in Patients With Chronic Kidney Disease After Kidney Transplant.

Campo Grande, Brazil; Research Site:
A Study of Subcutaneous Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.

Cariacica, Brazil; Research Site:
A Study of Subcutaneous Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.

Curitiba, Brazil; Research Site:
A Study of Subcutaneous Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.

Curitiba, Brazil; Research Site:
A Study of Mircera for the Treatment of Anemia in Dialysis Patients

Curitiba, Brazil; Research Site:
A Study of Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients.

Curitiba, Brazil; Research Site:
LATINO Study: A Study of Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.

Fortaleza, Brazil; Research Site:
A Study of Subcutaneous Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.

Fortaleza, Brazil; Research Site:
LATINO Study: A Study of Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.

Jaboatão Dos Guararapes, Brazil; Research Site:
A Study of Subcutaneous Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.

Jaú, Brazil; Research Site:
(BRAVE Study) - A Study of NeoRecormon (Epoetin Beta) in Patients With Metastatic Breast Cancer

Joinville, Brazil; Research Site:
A Study of Subcutaneous Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.

Juiz De Fora, Brazil; Research Site:
A Study of Subcutaneous Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.

Juiz De Fora, Brazil; Research Site:
A Study of Subcutaneous Mircera, Versus no ESA Therapy, in the Treatment of Anemia in Patients With Chronic Kidney Disease After Kidney Transplant.

Londrina, Brazil; Research Site:
A Study of Subcutaneous Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.

Natal, Brazil; Research Site:
A Study of Subcutaneous Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.

Porto Alegre, Brazil; Research Site:
A Study of Subcutaneous Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.

Porto Alegre, Brazil; Research Site:
A Study of Subcutaneous Mircera, Versus no ESA Therapy, in the Treatment of Anemia in Patients With Chronic Kidney Disease After Kidney Transplant.

Porto Alegre, Brazil; Research Site:
(BRAVE Study) - A Study of NeoRecormon (Epoetin Beta) in Patients With Metastatic Breast Cancer

Ribeirão Preto, Brazil; Research Site:
A Study of Subcutaneous Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.

Ribeirão Preto, Brazil; Research Site:
A Study of Mircera for the Treatment of Anemia in Dialysis Patients

Rio De Janeiro, Brazil; Research Site:
A Study of Subcutaneous Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.

Salvador, Brazil; Research Site:
A Study of Subcutaneous Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.

Sao Jose do Rio Preto, Brazil; Research Site:
A Study of Subcutaneous Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.

Sao Luis, Brazil; Research Site:
A Study of Subcutaneous Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.

Sao Paulo, Brazil; Research Site:
A Study of Subcutaneous Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.

Sao Paulo, Brazil; Research Site:
A Study of Subcutaneous Mircera, Versus no ESA Therapy, in the Treatment of Anemia in Patients With Chronic Kidney Disease After Kidney Transplant.

Sao Paulo, Brazil; Research Site:
A Study of Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients.

Sao Paulo, Brazil; Research Site:
(ACORD Study) - A Study of NeoRecormon (Epoetin Beta) in Patients With Early Diabetic Nephropathy

Sao Paulo, Brazil; Research Site:
A Study of Mircera for the Treatment of Anemia in Dialysis Patients

Sao Paulo, Brazil; Research Site:
LATINO Study: A Study of Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.

Sorocaba, Brazil; Research Site:
A Study of Subcutaneous Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.

Plovdiv, Bulgaria; Research Site:
A Study of NeoRecormon (Epoetin Beta) in Patients With Solid Tumors or Hematologic Malignancies

Sofia, Bulgaria; Research Site:
A Study of NeoRecormon (Epoetin Beta) in Patients With Solid Tumors or Hematologic Malignancies

Sofia, Bulgaria; Research Site:
A Study of NeoRecormon (Epoetin Beta) in Predialysis Patients With Renal Anemia

Stara Zagora, Bulgaria; Research Site:
A Study of NeoRecormon (Epoetin Beta) in Patients With Solid Tumors or Hematologic Malignancies

Varna, Bulgaria; Research Site:
A Study of NeoRecormon (Epoetin Beta) in Patients With Solid Tumors or Hematologic Malignancies

Varna, Bulgaria; Research Site:
A Study of NeoRecormon (Epoetin Beta) in Predialysis Patients With Renal Anemia

Calgary, AB, Canada; Research Site:
A Study of Subcutaneous Mircera in Patients With Chronic Kidney Disease, Not on Dialysis.

Calgary, AB, Canada; Research Site:
A Study of Mircera for the Maintenance Treatment of Anemia in Dialysis Patients.

Calgary, AB, Canada; Research Site:
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients.

Calgary, AB, Canada; Research Site:
A Study of Mircera in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis

Edmonton, AB, Canada; Research Site:
A Study of Subcutaneous Mircera Once Monthly in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis.

Edmonton, AB, Canada; Research Site:
A Study of Mircera in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis

Edmonton, AB, Canada; Research Site:
A Study of Mircera in Anemic Patients With Chronic Kidney Disease Not Yet on Dialysis.

Edmonton, AB, Canada; Research Site:
A Study of Mircera in the Long Term Treatment of Patients With Renal Anemia.

Edmonton, AB, Canada; Research Site:
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients.

Greenfield Park, QC, Canada; Research Site:
A Study of Intravenous or Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients

Greenfield Park, QC, Canada; Research Site:
A Study of Mircera in the Long Term Treatment of Patients With Renal Anemia.

Greenfield Park, QC, Canada; Research Site:
A Study of Mircera for the Maintenance Treatment of Anemia in Dialysis Patients.

Halifax, NS, Canada; Research Site:
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients.

Halifax, NS, Canada; Research Site:
A Study of Mircera in Patients With Non-Hodgkin's Lymphoma and Anemia.

Hamilton, ON, Canada; Research Site:
A Study of Mircera for the Maintenance Treatment of Anemia in Dialysis Patients.

Kamloops, BC, Canada; Research Site:
A Study of Mircera in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis

Kamloops, BC, Canada; Research Site:
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients.

Kingston, ON, Canada; Research Site:
A Study of Mircera for the Treatment of Anemia in Dialysis Patients

Kingston, ON, Canada; Research Site:
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients

Kingston, ON, Canada; Research Site:
A Study of Mircera in the Long Term Treatment of Patients With Renal Anemia.

Kingston, ON, Canada; Research Site:
A Study of Subcutaneous Mircera in Patients With Chronic Kidney Disease, Not on Dialysis.

Kitchener, ON, Canada; Research Site:
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients.

Kitchener, ON, Canada; Research Site:
A Study of Mircera in the Long Term Treatment of Patients With Renal Anemia.

Kitchener, ON, Canada; Research Site:
A Study of Mircera in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis

Kitchener, ON, Canada; Research Site:
A Study of Mircera for the Maintenance Treatment of Anemia in Dialysis Patients.

London, ON, Canada; Research Site:
A Study of Subcutaneous Mircera Once Monthly in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis.

London, ON, Canada; Research Site:
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients

London, ON, Canada; Research Site:
A Study of Mircera in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis

London, ON, Canada; Research Site:
A Study of Mircera for the Treatment of Anemia in Dialysis Patients

London, ON, Canada; Research Site:
A Study of Mircera in the Long Term Treatment of Patients With Renal Anemia.

Mississauga, ON, Canada; Research Site:
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients.

Mississauga, ON, Canada; Research Site:
A Study of Mircera in the Long Term Treatment of Patients With Renal Anemia.

Mississauga, ON, Canada; Research Site:
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients

Mississauga, ON, Canada; Research Site:
A Study of Mircera for the Maintenance Treatment of Anemia in Dialysis Patients.

Mississauga, ON, Canada; Research Site:
A Study of Subcutaneous Mircera in Patients With Chronic Kidney Disease, Not on Dialysis.

Montreal, QC, Canada; Research Site:
A Study of Subcutaneous Mircera Once Monthly in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis.

Montreal, QC, Canada; Research Site:
A Study of Subcutaneous Mircera in Patients With Chronic Kidney Disease, Not on Dialysis.

Montreal, QC, Canada; Research Site:
A Study of Intravenous or Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients

Montreal, QC, Canada; Research Site:
A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving Chemotherapy.

Montreal, QC, Canada; Research Site:
A Study of Mircera in Anemic Patients With Chronic Kidney Disease Not Yet on Dialysis.

Montreal, QC, Canada; Research Site:
A Study of Mircera in the Long Term Treatment of Patients With Renal Anemia.

Montreal, QC, Canada; Research Site:
A Study of Mircera for the Treatment of Anemia in Dialysis Patients

Montreal, QC, Canada; Research Site:
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients

Montreal, QC, Canada; Research Site:
A Study of Mircera in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis

New Westminster, BC, Canada; Research Site:
A Study of Mircera in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis

North Vancouver, BC, Canada; Research Site:
A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving Chemotherapy.

Ottawa, ON, Canada; Research Site:
A Study of Mircera in Patients With Non-Hodgkin's Lymphoma and Anemia.

Ottawa, ON, Canada; Research Site:
A Study of Intravenous or Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients

Ottawa, ON, Canada; Research Site:
A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving Chemotherapy.

Ottawa, ON, Canada; Research Site:
A Study of Mircera for the Maintenance Treatment of Anemia in Dialysis Patients.

Sainte-Foy, QC, Canada; Research Site:
A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving Chemotherapy.

Saskatoon, SK, Canada; Research Site:
A Study of Mircera in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis

Saskatoon, SK, Canada; Research Site:
A Study of Mircera in the Long Term Treatment of Patients With Renal Anemia.

Saskatoon, SK, Canada; Research Site:
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients

Scarborough, ON, Canada; Research Site:
A Study of Mircera in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis

Scarborough, ON, Canada; Research Site:
A Study of Mircera in the Long Term Treatment of Patients With Renal Anemia.

St John'S, Canada; Research Site:
A Study of Mircera in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis

St John'S, Canada; Research Site:
A Study of Mircera for the Treatment of Anemia in Dialysis Patients

St John'S, Canada; Research Site:
A Study of Subcutaneous Mircera in Patients With Chronic Kidney Disease, Not on Dialysis.

St John'S, Canada; Research Site:
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients

St John'S, Canada; Research Site:
A Study of Mircera in Patients With Non-Hodgkin's Lymphoma and Anemia.

Surrey, BC, Canada; Research Site:
A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving Chemotherapy.

Toronto, ON, Canada; Research Site:
A Study of Subcutaneous Mircera Once Monthly in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis.

Toronto, ON, Canada; Research Site:
A Study of Subcutaneous Mircera in Patients With Chronic Kidney Disease, Not on Dialysis.

Toronto, ON, Canada; Research Site:
A Study of Mircera in Patients With Non-Hodgkin's Lymphoma and Anemia.

Toronto, ON, Canada; Research Site:
A Study of Intravenous or Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients

Toronto, ON, Canada; Research Site:
A Study of Mircera in the Long Term Treatment of Patients With Renal Anemia.

Toronto, ON, Canada; Research Site:
A Study of Mircera for the Maintenance Treatment of Anemia in Dialysis Patients.

Toronto, ON, Canada; Research Site:
A Study of Mircera for the Treatment of Anemia in Dialysis Patients

Toronto, ON, Canada; Research Site:
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients

Toronto, ON, Canada; Research Site:
A Study of Mircera in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis

Trois-Rivieres, QC, Canada; Research Site:
A Study of Mircera for the Maintenance Treatment of Anemia in Dialysis Patients.

Vancouver, BC, Canada; Research Site:
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients.

Vancouver, BC, Canada; Research Site:
A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving Chemotherapy.

Vancouver, BC, Canada; Research Site:
A Study of Mircera in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis

Weston, ON, Canada; Research Site:
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients

Weston, ON, Canada; Research Site:
A Study of Subcutaneous Mircera in Patients With Chronic Kidney Disease, Not on Dialysis.

Winnipeg, MB, Canada; Research Site:
A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients.

Winnipeg, MB, Canada; Research Site:
A Study of Mircera in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis

Winnipeg, MB, Canada; Research Site:
A Study of Mircera for the Treatment of Anemia in Dialysis Patients

Santiago, Chile; Research Site:
LATINO Study: A Study of Mircera for the Maintenance Treatment of Dialysis Patients With Chronic Renal Anemia.

Beijing, China; Research Site:
A Study Comparing Mircera and Epoetin Beta for the Treatment of Anemia in Dialysis Patients With Chronic Kidney Disease.

Beijing, China; Research Site:
A Study of NeoRecormon (Epoetin Beta) for Prevention and Treatment of Anemia in Patients With Solid Tumors Receiving Platinum-Based Chemotherapy Prone to Induce Anemia

Beijing, China; Research Site:
A Study of NeoRecormon (Epoetin Beta) for Treatment of Anemia in Patients With Hematologic Malignancies.

Chengdu, China; Research Site:
A Study Comparing Mircera and Epoetin Beta for the Treatment of Anemia in Dialysis Patients With Chronic Kidney Disease.

Guangzhou, China; Research Site:
A Study of NeoRecormon (Epoetin Beta) for Prevention and Treatment of Anemia in Patients With Solid Tumors Receiving Platinum-Based Chemotherapy Prone to Induce Anemia

Guangzhou, China; Research Site:
A Study Comparing Mircera and Epoetin Beta for the Treatment of Anemia in Dialysis Patients With Chronic Kidney Disease.

Hong Kong, China; Research Site:
A Study of Subcutaneous Mircera Once Monthly in the Treatment of Anemia in Patients With Chronic Kidney Disease Not on Dialysis.

Hong Kong, China; Research Site:
A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving Chemotherapy.

Hong Kong, China; Research Site:
A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving First Line Chemotherapy.

Hong Kong, China; Research Site:
A Study of Treatment With NeoRecormon (Epoetin Beta) in Patients With Chronic Renal Anemia

Hong Kong, China; Research Site:
A Study Comparing Mircera and Epoetin Beta for the Treatment of Anemia in Dialysis Patients With Chronic Kidney Disease.

Shanghai, China; Research Site:
A